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INTRODUC TION
Colorectal cancer is the fourth most common cancer in the UK, with 
around 42 000 new cases per year, and the second leading cause 
of cancer-related death [1]. Approximately 20% of colorectal cancer 
patients will have metastases at diagnosis and they will subsequently 
become apparent in up to 50% of people [2]. Around 5%–15% of 
patients with cancer of the colon will develop metastases in the 
lungs during the disease course, and such spread is proportionally 
more common in rectal cancer patients, because of the difference 
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Abstract
Aim: Evidence on patterns of use of pulmonary metastasectomy in colorectal cancer pa-
tients is limited. This population-based study aims to investigate the use of pulmonary 
metastasectomy in the colorectal cancer population across the English National Health 
Service (NHS) and quantify the extent of any variations in practice and outcome.
Methods: All adults who underwent a major resection for colorectal cancer in an NHS hos-
pital between 2005 and 2013 were identified in the COloRECTal cancer data Repository 
(CORECT-R). All inpatient episodes corresponding to pulmonary metastasectomy, occur-
ring within 3 years of the initial colorectal resection, were identified. Multi-level logis-
tic regression was used to determine patient and organizational factors associated with 
the use of pulmonary metastasectomy for colorectal cancer, and Kaplan–Meier and Cox 
models were used to assess survival following pulmonary metastasectomy.
Results: In all, 173 354 individuals had a major colorectal resection over the study period, 
with 3434 (2.0%) undergoing pulmonary resection within 3 years. The frequency of pul-
monary metastasectomy increased from 1.2% of patients undergoing major colorectal 
resection in 2005 to 2.3% in 2013. Significant variation was observed across hospital pro-
viders in the risk-adjusted rates of pulmonary metastasectomy (0.0%–6.8% of patients). 
Overall 5-year survival following pulmonary resection was 50.8%, with 30-day and 90-
day mortality of 0.6% and 1.2% respectively.
Conclusions: This study shows significant variation in the rates of pulmonary metastasec-
tomy for colorectal cancer across the English NHS.
K E Y W O R D S
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in venous drainage between colon and rectum, with reported fig-
ures of between 11% and 19% [2,3]. Lung only or, probably more 
correctly, lung-first metastases are uncommon in colorectal cancer, 
however, with around 80%–85% of patients also having metastases 
in other sites, most frequently the liver [2].
There are several important recent influences on surgi-
cal practice within the National Health Service (NHS) with re-
spect to colorectal lung metastases. First, the Association of 
Coloproctology of Great Britain and Northern Ireland (ACPGBI), 
in its Improving Management of Patients with Advanced 
Colorectal Tumours (IMPACT) initiative in 2017, has promoted 
an active policy of monitoring, detecting and team discussions to 
offer further treatment [4]. A Delphi project run by the ACPGBI 
ranked management of lung metastases high in its research pri-
orities [5]. Second, the National Institute for Health and Clinical 
Excellence (NICE), which provides guidance for the NHS, pub-
lished guidance on the management of metastatic disease in col-
orectal cancer in January 2020. They found no randomized trials 
and based their guidance on a ‘very low quality’ follow-up anal-
ysis [6] but still recommended that lung metastasectomy should 
be ‘considered’ [7]. Finally, the Society of Thoracic Surgeons 
Consensus Document on Pulmonary Metastasectomy in 2019 [8] 
again, despite acknowledging the lack of randomized evidence, 
gave as their first recommendation that pulmonary metastasec-
tomy should be ‘considered’ and ‘carefully individualized’ [8].
‘Pulmonary metastasectomy in colorectal cancer’, published in 
2020 [9,10], was the first randomized trial on this topic. Patients were 
randomized to lung metastasectomy (N = 46) or control (N = 47) and 
87% were followed for more than 5 years or until death. There was 
no significant difference comparing metastasectomy to controls; 
the hazard ratio (HR) for death was 0.93 (95% CI 0.56, 1.56). This 
puts into question the recommendations for practice from ACPGBI, 
Society of Thoracic Surgeons and NICE.
It had been estimated that 15%–25% of those with pulmo-
nary metastases were being considered for local treatments [11]. 
Traditionally surgery has been the main local treatment, but more 
recently image guided thermal ablation (IGTA), including radiofre-
quency, microwave or cryoablation, and stereotactic radiotherapy 
(variously abbreviated as SABR or SBRT) have been increasingly 
used as alternatives. Each has been tested in a randomized con-
trolled trial [12,13] but, unfortunately, both had major imbalances 
across trial arms so, again, it is not clear what constitutes gold stan-
dard care.
Further studies with an emphasis on understanding the ex-
tent and characteristics of patients with metastases are required. 
Arguably more information is required about the disease in its to-
tality rather than outcomes amongst patients carefully selected for 
local treatments. Most existing studies on pulmonary metastasec-
tomy are single-centre surgical case series [8] with very few pop-
ulation-based cohorts or registry studies [14–17]. When the larger 
series within these studies are considered, the incidence of pulmo-
nary metastasectomy is estimated to be only around 2.5% [14,16] 
of all colorectal cancer patients and 3.5%–5% [14,17] of those with 
metastases at diagnosis. As such, pulmonary metastasectomy is 
clearly used in a highly selectively manner.
This population-based study therefore aimed to investigate the 
use of pulmonary metastasectomy in the colorectal cancer popula-
tion across the English NHS and to quantify the extent of any varia-
tions in practice and outcome.
METHODS
All adults diagnosed with a first primary colorectal cancer (ICD-
10 codes C18–C20), and who had undergone a major resection 
for their disease in an NHS hospital with a multidisciplinary team 
(MDT) between 1 January 2005 and 31 December 2013 (to allow 
3 years of follow-up until censoring at December 2016), were 
identified in the COloRECTal cancer data Repository (CORECT-R). 
This resource contains numerous linked population-level datasets 
relevant to colorectal cancer and, for this study, information was 
derived from a linked National Cancer Registration and Analysis 
Service (NCRAS) and Hospital Episode Statistics (HES) dataset. 
Information on date of diagnosis, age, sex, site and stage of tu-
mour and deprivation (measured via the income domain of the 
Index of Multiple Deprivation [IMD] 2010), were extracted from 
the cancer registry dataset. Where patients had multiple tumours 
recorded simultaneously, the tumour with the highest stage was 
selected. Any remaining duplicate patient records were cleaned to 
select the most relevant tumour for the type of major resection 
carried out. Information on the type and date of the first major 
resection surgery following diagnosis was extracted from the HES 
component of CORECT-R. Major primary resection for colorec-
tal cancer and lung resection were identified by the appropriate 
OPCS 4.8 codes (Appendix Table S1). The lung resection codes 
were presumed to correspond to pulmonary metastasectomy. It 
is possible that some of these procedures may have been carried 
out for primary lung cancer or other diagnoses, due to the ab-
sence of additional information. Primary tumours of the caecum, 
appendix, ascending colon, hepatic flexure and transverse colon 
(ICD-10 codes C18.0–C18.4) were assigned as right-sided colon 
tumours, whilst tumours in the splenic flexure, descending colon, 
sigmoid colon and rectosigmoid (ICD-10 C18.5–C19) were as-
signed as left-sided colon tumours. Rectal tumours were assigned 
What does this paper add to the literature?
There is limited population-based evidence available on 
patterns of pulmonary metastasectomy for colorectal 
cancer lung metastases. This is one of the first studies to 
use large population-level, linked datasets to investigate 
practice and outcomes following such surgery across the 
English National Health Service.
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using ICD-10 C20. Where more than one OPCS procedure code 
appeared on the same day for the lung resection, the most exten-
sive operation was selected.
The Charlson Comorbidity Index (CCI) [18] was derived for each 
patient, taking into account diagnoses (excluding cancer) from any 
hospital admissions in the year preceding diagnosis of colorectal 
cancer. The cancer component of the CCI was derived from the can-
cer registry information in CORECT-R and added to that obtained 
from HES data. The CCI was categorized as 0, 1, 2 and ≥3 with higher 
scores indicating greater degree of comorbidity.
Data from the Organizational Survey 2016, carried out by the 
National Bowel Cancer Audit [19] were used to identify whether the 
initial colorectal resection was carried out within an MDT with an 
on-site specialist thoracic team. Twenty-five specialist thoracic sur-
gery centres were identified in the data out of 146 Trusts.
Multi-level logistic regression was used to determine factors 
associated with the use of resection for lung metastases. Models 
were constructed with patients clustered within hospitals, which 
were then further clustered within Cancer Alliances. Explanatory 
variables in the risk-adjusted model were age at resection, sex, IMD 
quintile, tumour site, year of primary major colorectal resection, CCI, 
stage at diagnosis, and whether the trust was a thoracic surgery cen-
tre. Funnel plots were constructed to show the variation in resection 
of metastases across MDTs using the Spiegelhalter approach [20] 
and those MDTs outside the 99.8% control limits were considered 
‘outliers’ in terms of their practice.
Survival was calculated from the date of lung metastasectomy 
until death, or censored on 31 December 2016. Overall survival 
following pulmonary metastasectomy was analysed using Kaplan–
Meier actuarial methods by sex, age at diagnosis, IMD quintile, site 
and stage of primary tumour at diagnosis and CCI. Log rank tests 
were used to test for any statistically significant difference between 
these groups. Cox proportional hazards regression analysis was used 
to determine factors associated with a higher risk of death following 
pulmonary metastasectomy surgery. Analyses were conducted using 
STATA 15 (StataCorp).
The best estimate of the representative median interval be-
tween primary colorectal cancer resection and pulmonary metasta-
sectomy operations is 29 months, based on data from seven reports 
from 2006 to 2013 including a total of 1606 operations [21–27]. 
Our 3-year cut-off will have missed some cases so a sensitivity anal-
ysis was also carried out to identify pulmonary metastasectomies 
within 5 years of primary colorectal resection. To ensure that all pa-
tients had full 5-year follow-up in the data (allowing analysis of tem-
poral trends), only patients undergoing primary resections between 
2005 and 2011 were selected for sensitivity analysis. Searching for 
pulmonary metastasectomies within 5 years captured an additional 
850 patients over the period (an average of 121 more patients an-
nually) compared to those within 3 years. This increase in cases was 
balanced against the loss of 2 years’ worth of data due to requiring 
5 full years of follow-up, so all subsequent data refer to pulmonary 
metastasectomies taking place within 3 years of the colorectal pri-
mary resection.
RESULTS
Surgical management of metastases
During the period 1 January 2005 to 31 December 2013, 173 354 
patients were identified as undergoing major resection for a colo-
rectal tumour, the characteristics of whom are outlined in Table 1. 
Of these 3434 (2.0%) underwent one or more resections for lung 
metastases within 3 years of their primary colorectal resection.
There were 2941 patients (85.6%) having one surgical episode, 
431 (12.6%) having two episodes and 62 (1.8%) having three or 
more within 3 years, giving a total of 3998 pulmonary metasta-
sectomy episodes. Looking at the extent of the first pulmonary 
procedure, 25 (0.7%) were pneumonectomies, 23 (0.7%) were 
bilobectomies, 895 (26.1%) were lobectomies and 2491 (72.5%) 
were sublobar resections. There were 574 patients (16.7%) who 
had previously had a liver resection at the time of their pulmonary 
resection, 85 (2.5%) who had a subsequent liver resection and 
seven patients (0.2%) had liver and pulmonary metastasectomy on 
the same day.
The percentage of patients receiving pulmonary metastasec-
tomy increased from around 1.2% of all patients in 2005, who un-
derwent a major resection for colorectal cancer, to 2.3% in 2013 
(Figure 1). The rate of pulmonary metastasectomy was higher for 
patients presenting with tumours in the rectum (3.17%) than for tu-
mours of the colon (1.49%) which is a reflection of the well docu-
mented difference in incidence due to the anatomical difference in 
venous drainage between the colon and rectum [2,28,29].
Multi-level logistic regression was performed using data from 
2010 to 2013, during which period staging of the primary tumour 
was more complete (Table 2). The likelihood of receiving surgery 
reduced with age (OR 0.23 for age >80 compared to the average 
age group 61–70; 95% CI 0.18–0.29). There was no significant dif-
ference in the rate of surgery between men and women or across 
deprivation quintiles. The odds of resection decreased with in-
creasing CCI (OR 0.44 for CCI 3 or more compared to a score of 
zero; 95% CI 0.27–0.71). Patients with rectal tumours were most 
likely to receive surgery (OR 2.61; 95% CI 2.30–2.97) and those 
with tumours in the right colon were the least likely to receive 
treatment for lung metastases. Patients with more advanced dis-
ease stage at diagnosis were more likely to undergo pulmonary 
metastasectomy within 3 years of their primary colorectal resec-
tion (OR for Stage IV vs. Stage III 1.77; 95% CI 1.55–2.03). These 
will include patients with synchronous metastases, which were 
already evident at the time of initial cancer staging. There was no 
statistically significant difference in the likelihood of pulmonary 
metastasectomy depending on whether patients received surgery 
for their colorectal primary in a trust with a specialist thoracic cen-
tre, in either the risk-adjusted or non-adjusted model.
There was a large degree of variation in the proportion of pa-
tients having a pulmonary metastasectomy when analysed by the 
hospital provider for their primary colorectal resection, with crude 
and risk-adjusted rates both between 0.0% and 6.8% (P < 0.001). By 
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TA B L E  1  Characteristics of the study population
No procedure (n = 169 920) Pulmonary metastasectomy (n = 3434) Total (n = 173 354)
Tumour site
Right colon 60 043 (35.3) 727 (21.2) 60 770 (35.1)
Caecum 27 259 (16.0) 345 (10.0) 27 604 (15.9)
Appendix 862 (0.5) 6 (0.2) 868 (0.5)
Ascending colon 16 609 (9.8) 240 (7.0) 16 849 (9.7)
Hepatic flexure 5452 (3.2) 61 (1.8) 5513 (3.2)
Transverse colon 9861 (5.8) 75 (2.2) 9936 (5.7)
Left colon 60 540 (35.6) 1210 (35.2) 61 750 (35.6)
Splenic flexure 4169 (2.5) 59 (1.7) 4228 (2.4)
Descending colon 5254 (3.1) 83 (2.4) 5337 (3.1)
Sigmoid colon 38 866 (22.9) 775 (22.6) 39 641 (22.9)
Rectosigmoid 12 251 (7.2) 293 (8.5) 12 544 (7.2)
Overlapping/unspecified lesion of colon 6270 (3.7) 88 (2.6) 6358 (3.7)
Rectum 43 067 (25.3) 1409 (41.0) 44 476 (25.7)
Sex
Male 95 279 (56.1) 2089 (60.8) 97 368 (56.2)
Female 74 641 (43.9) 1345 (39.2) 75 986 (43.8)
Age at primary colorectal resection
≤60 33 362 (19.6) 964 (28.1) 34 326 (19.8)
61–70 48 772 (28.7) 1320 (38.4) 50 092 (28.9)
71–80 57 268 (33.7) 1029 (30.0) 58 297 (33.6)
>80 30 518 (18.0) 121 (3.5) 30 639 (17.7)
Year of primary colorectal resection
2005 16 233 (9.6) 203 (5.9) 16 436 (9.5)
2006 17 864 (10.5) 283 (8.2) 18 147 (10.5)
2007 18 335 (10.8) 329 (9.6) 18 664 (10.8)
2008 19 103 (11.2) 390 (11.4) 19 493 (11.2)
2009 19 355 (11.4) 390 (11.4) 19 745 (11.4)
2010 19 975 (11.8) 452 (11.8) 20 427 (11.8)
2011 20 092 (11.8) 461 (13.4) 20 553 (11.9)
2012 20 195 (11.9) 492 (14.3) 20 687 (11.9)
2013 18 768 (11.0) 434 (12.6) 19 202 (11.1)
Tumour stage at diagnosis
I 23 353 (13.7) 326 (9.5) 23 679 (13.7)
II 58 088 (34.2) 988 (28.8) 59 076 (34.1)
III 57 394 (33.8) 1266 (36.9) 58 660 (33.8)
IV 13 322 (7.8) 511 (14.9) 13 833 (8.0)
Unknown 17 763 (10.5) 343 (10.0) 18 106 (10.4)
IMD quintile
1, least deprived 36 582 (21.5) 739 (21.5) 37 321 (21.5)
2 38 637 (22.7) 832 (24.2) 39 469 (22.8)
3 35 746 (21.0) 687 (20.0) 36 433 (21.0)
4 31 661 (18.6) 590 (17.2) 32 251 (18.6)
5, most deprived 27 294 (16.1) 586 (17.1) 27 880 (16.1)
(Continues)
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Cancer Alliance/Vanguard the crude rate varied between 1.5% and 
3.1% (P = 0.003) and the risk-adjusted rate varied between 1.5% for 
Lancashire and Cumbria and 3.0% for South East London; however, 
there was no statistically significant difference between Cancer 
Alliances following risk adjustment (Figure 2).
Survival
Overall median survival following pulmonary metastasectomy was 
44 months, with 1, 3 and 5 years at 91.6%, 67.9% and 50.8% respec-
tively. Thirty-day and 90-day postoperative mortality were 0.6% and 
1.2% respectively. Women had higher overall survival than men (5-
year survival of 53.6% vs. 49.0%, P = 0.045); however, once adjusted 
for patient and tumour characteristics, this difference was not sig-
nificant. Older patients had reduced survival following lung metasta-
sectomy (5-year survival of 53.0% for those ≤60 compared to 43.5% 
for those >80, adjusted HR 1.68, 95% CI 1.30–2.16) (Table 3). There 
was no statistically significant difference in overall survival across 
deprivation quintile (5-year survival of 53.8% for least deprived vs. 
47.8% for most deprived); however, when adjusted for patient and 
tumour characteristics there was a statistically significant reduction 
in survival after pulmonary metastasectomy for the most deprived 
group compared to the least deprived group (HR 1.18, 95% CI 1.02–
1.37, P = 0.030). There was an increase in HR with increasing comor-
bidity (HR 1.78, 95% CI 1.13–2.81). Patients with primary tumours in 
the left colon had improved survival compared to all other sites (HR 
0.87, 95% CI 0.76–0.99; Figure 3).
Patients who had a prior liver resection had a 5-year survival of 
37.8% post-pulmonary metastasectomy, whilst those who had not 
undergone a liver resection had a 5-year survival of 53.7% following 
pulmonary metastasectomy (P < 0.001). The Kaplan–Meier survival 
curve in Figure 4 suggests improved survival for those undergo-
ing sublobar excision compared to lobectomy until around 5 years, 
when there is no observed difference between the two procedures. 
It is not possible to know how much this association was influenced 
by the severity of the disease or the treatment. There are few pneu-
monectomies and bilobectomies and survival was much worse for 
these patients compared to those undergoing lobectomy; again the 
disease and the treatment was more severe.
Potential volume effects on survival outcomes were considered; 
however, there was no statistically significant difference in 5-year 
survival following pulmonary metastasectomy between high, mid 
and low volume providers. There was no correlation between the 
crude or adjusted pulmonary resection rate and 5-year survival by 
Cancer Alliance or MDT.
DISCUSSION
This large population-based study demonstrates that there has been 
an increase in the rate of pulmonary metastasectomy between 2005 
and 2013, with the rate remaining constant at around 2.3% for the 
later years of 2010–2013. Increases in the frequency of pulmo-
nary metastasectomy were also observed in the American National 
Inpatient Sample between 2000 and 2011 [30]. Previous studies 
have estimated the incidence of pulmonary metastasectomy to be 
within 1%–2.5% for all colorectal cancer patients [14,16]. The English 
NHS national figure of 2.3% is at the higher end of this range. When 
considering the number of patients receiving pulmonary metasta-
sectomy, within 3 years of diagnosis, as a proportion of all colorectal 
cancer patients diagnosed with their first tumours between 2005 
No procedure (n = 169 920) Pulmonary metastasectomy (n = 3434) Total (n = 173 354)
Charlson Comorbidity Index
0 135 383 (79.7) 2881 (83.9) 138 264 (79.8)
1 23 878 (14.1) 434 (12.6) 24 312 (14.0)
2 6705 (3.9) 90 (2.6) 6795 (3.9)
≥3 3954 (2.3) 29 (0.8) 3983 (2.3)
Note:: Values in parentheses are percentages.
Abbreviation: IMD, index of multiple deprivation.
TABLE 1 (Continued)
F I G U R E  1  Percentage of patients receiving a pulmonary 
resection within 3 years of their primary colorectal resection as a 
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and 2013, then a figure of 1.36% for the English NHS over the whole 
series and 1.5% for the later years 2010–2013 is obtained. There 
appear to be no large population-based studies to enable direct 
comparison. The rate of pulmonary metastasectomy in patients with 
rectal cancer was twice that for patients with tumours in the colon. 
This reflects the higher rate of metastasis to the lungs in rectal can-
cer, related to the anatomical differences in venous drainage already 
noted [2,28,29].
Postoperative 30- and 90-day mortality of 0.6% and 1.2% re-
spectively shows lung metastasectomy to be relatively safe. Overall 
5-year survival following pulmonary metastasectomy was 50.8%. 
This national figure falls within the range reported by a number of 
single-centre studies which report rates varying between 27% and 
66% [8,31,32].
Receiving surgery for the primary colorectal tumour, in a trust 
with a specialist thoracic surgical centre on-site, did not increase 
the chances of a patient receiving pulmonary resection in either the 
risk-adjusted or unadjusted model. This contrasts with liver metas-
tasectomy whereby patients with colorectal cancer liver metastases 
are more likely to receive surgical resection when their primary col-
orectal tumour is resected in a hospital with an on-site hepatobiliary 
team [33]. This also contrasts with studies carried out on primary 
non-small-cell lung cancer, which suggest that being seen first in a 
specialist thoracic surgical centre increases the likelihood of receiv-
ing lung surgery [34].
There was significant variation in the percentage of patients re-
ceiving a pulmonary resection between trusts, with two trusts hav-
ing higher than average pulmonary metastasectomy rates, that is, 
outside of the 99.8% confidence limits so outside of the ‘random’ 
variation that would be expected, and one trust having a lower 
than average pulmonary metastasectomy rate of only 0.14% of pa-
tients. Whilst there were significant differences in the crude rate 
of pulmonary metastasectomy by the Cancer Alliance within which 
the patient received their colorectal resection, this was no longer 
observed following risk adjustment for patient and tumour char-
acteristics. Therefore it seems that referral practice is similar at a 
regional level, with more variation occurring on a hospital site level. 
This variation may also be affected by trusts referring patients for 
ablation or SBRT rather than resection. Data on ablation were not 
fully captured during this work due to a large amount of variation in 
coding practice. Exploring this will form the basis for future work. 
Current NICE draft guidance [7] suggests that there is insufficient 
evidence to recommend one type of local treatment over another 
so either surgical resection, ablation or SBRT should be considered 
for people with colorectal lung metastases. It will be interesting to 
note whether trusts with lower resection rates refer larger numbers 
of patients for ablation or SBRT and whether patients have similar 
access to all treatments across trusts.
The rate of pulmonary metastasectomy in the over 80s group 
was almost one-fifth of that for patients aged 71–80; however, there 
F I G U R E  2  Organization funnel plots showing the variation in (A) unadjusted pulmonary metastasectomy rate by trust, (B) risk-adjusted 
pulmonary metastasectomy rate by trust, (C) unadjusted pulmonary metastasectomy rate by Cancer Alliance and (D) risk-adjusted 
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was no statistically significant difference in 5-year survival between 
the two age groups. Five-year survival following surgery for lung 
metastases for the over 80s group was 43.5%. The postoperative 
mortality and 5-year survival outcomes in the group receiving me-
tastasectomy, along with the small numbers of over 80s undergoing 
lung surgery, suggests that the threshold for lung metastasectomy 
is extremely high within this population and only the fittest pa-
tients receive surgery. However, older patients may be more likely 
to undergo less invasive ablative treatments rather than resection. 
Unfortunately, we do not have information on the frequency of 
ablative treatments or radiotherapy in order to assess whether they 
receive alternative treatment.
There was no statistically significant difference in the likelihood 
of receiving a pulmonary metastasectomy across different depri-
vation quintiles, in contrast to the trend observed for resection for 
colorectal cancer liver metastases [35] or resection for primary lung 
cancer where more deprived patients are less likely to receive pul-
monary resection [36,37].
One limitation of this study is that there is not sufficient infor-
mation to ascertain the reason for the lung resection. It has been 




HR 95% CI P
Adjusted 
HR 95% CI P
Year of resection of colorectal primary 0.96 0.94 0.98 <0.001 0.95 0.93 0.97 <0.001
Primary colorectal resection carried 
out in hospital with thoracic centre
1.07 0.96 1.20 <0.203 1.05 0.94 1.17 0.413
Age at resection of colorectal primary
≤60 1.00 1.00
61–70 1.00 0.88 1.12 0.944 1.02 0.90 1.15 0.727
71–80 1.30 1.15 1.47 <0.001 1.38 1.22 1.56 <0.001
>80 1.48 1.16 1.89 0.002 1.68 1.30 2.16 <0.001
Sex
Male 1.00 1.00
Female 0.86 0.78 0.94 0.002 0.86 0.78 0.95 0.003
IMD quintile
1, least deprived 1.00 1.00
2 1.05 0.92 1.21 0.469 1.05 0.91 1.20 0.533
3 1.06 0.92 1.23 0.435 1.05 0.90 1.21 0.541
4 1.14 0.98 1.32 0.100 1.15 0.99 1.34 0.074
5, most deprived 1.17 1.01 1.36 0.036 1.18 1.02 1.37 0.030
Stage of primary tumour at diagnosis
I 1.00 1.00
II 1.15 0.95 1.40 0.143 1.14 0.94 1.39 0.183
III 1.54 1.28 1.85 <0.001 1.60 1.33 1.93 <0.001
IV 1.58 1.29 1.94 <0.001 1.74 1.41 2.14 <0.001
Unknown 1.55 1.25 1.93 <0.001 1.53 1.23 1.91 <0.001
Tumour site
Right colon 1.00 1.00
Left colon 0.85 0.74 0.96 0.010 0.86 0.76 0.98 0.022
Rectum 0.98 0.89 1.11 0.740 1.01 0.89 1.14 0.910
Colon unknown 1.18 0.87 1.57 0.258 1.18 0.88 1.57 0.266
Charlson Comorbidity Index
0 1.00 1.00
1 1.13 0.98 1.30 0.093 1.14 0.99 1.31 0.068
2 1.37 1.04 1.81 0.026 1.36 1.03 1.80 0.031
≥3 1.80 1.14 2.82 0.011 1.78 1.13 2.81 0.013
Abbreviations: HR, hazard ratio; IMD, index of multiple deprivation.
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presumed that these surgical procedures are taking place due to pul-
monary metastases, given the proximity to diagnosis of colorectal 
cancer; however, it is also possible that patients received surgery for 
other diagnoses such as primary lung cancer or emphysema.
CONCLUSION
This study comprises the first large population-based analysis of the 
use of pulmonary metastasectomy for colorectal cancer lung metas-
tases. The rate of pulmonary metastasectomy in the population un-
dergoing major colorectal resection within the NHS is around 2.3% in 
the later part of the study; however, it must be noted that this figure 
does not provide a full picture of the number of patients undergoing 
local treatment for pulmonary metastasis, as it does not account for 
those who may be undergoing IGTA or SABR as an alternative treat-
ment to surgery. Previous studies have shown that the likelihood of 
receiving liver resection surgery for metastatic colorectal cancer is 
affected by the presence of an on-site specialist hepatobiliary centre 
in the hospital where the patient first receives their colorectal resec-
tion. In this study, there was no statistically significant difference in 
the likelihood of pulmonary metastasectomy depending on whether 
the patient underwent their colorectal surgery in a hospital with a 
specialist thoracic centre on-site or not. There was variation in the 
rate of pulmonary metastasectomy across hospitals, however, which 
remained after accounting for patient and tumour characteristics. 
F I G U R E  4  Kaplan–Meier survival 
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F I G U R E  3  Kaplan–Meier survival curves grouped by sex, tumour site, tumour stage, age and diagnosis, IMD quintile and Charlson 
Comorbidity Index score
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Further randomized studies are urgently required to establish if 
there is a survival benefit from local treatment of lung metastases 
and, if so, for which patients. Such studies should allow optimization 
of the management of pulmonary metastases from colorectal cancer 
in the English NHS.
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